Archive for July, 2021

$XPHYF Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care. “We believed in 3a’s research and development plan from the beginning, when we signed the first collaboration contract in 2020. Now that XPhyto has announced the pending acquisition of 3a, we are particularly excited about this development milestone,” said Wolfgang Probst, director and COO of XPhyto. “Successful validation of the first biosensor candidates demonstrates the expertise and scientific excellence at 3a. Since the co-developed and successfully approved German CE marked 25-minute PCR test in March of this year, this novel approach for oral biosensor screening is another important milestone towards development of tools to effectively identify infectious breakouts of COVID-19 to reduce the pandemic spread and help find our way back to the new normal.”

To view the full press release, visit https://ibn.fm/9IRmt

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $XPHYF Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

$SRAX Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors

July 28, 2021

SRAX Inc. (NASDAQ: SRAX) Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors

  • Registered Investment Advisors and retail investors cumulatively account for significant proportion of US equity market assets under management
  • SRAX’s Sequire platform bridges gap between corporations and their end investors
  • SRAX recently introduced automated email and SMS functions, allowing companies to efficiently communicate with millions of retail investors on their platform
  • Listed companies will also be able to search and interact with investment advisor community through Sequire’s proprietary search functions

Investment advisors make up a huge segment of the U.S. investor base; according to a recent survey carried out by RIA Channel, there were 14,955 independent registered investment advisors in the United States with cumulative assets under management of $2.969 trillion (https://ibn.fm/gkVER). Meanwhile, retail investors have increasingly become a dominant force within the U.S. equity market; a study carried out by Morgan Stanley revealed that retail investors accounted for close to 10 percent of daily trading volume on the Russell 3000, the broadest U.S. stocks index, after peaking at 15% in September 2020 as widespread lockdowns and increased savings triggered interest in the markets (https://ibn.fm/ecxI4). SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has sought to bridge the gap between listed corporations and the two investor sub-sets through the introduction of a number of novel features on its platform.

As of May 2021, SRAX revealed that its Sequire platform had seen its corporate subscriber base swell to 183 publicly listed companies in addition to boasting a network of over five million influential, forward-thinking investors and shareholders. Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function.

Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories (https://ibn.fm/mmDe2), along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform.

“These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,” said SRAX Founder and CEO Christopher Miglino (https://ibn.fm/u0ITG).

SRAX has simultaneously released new search features, enabling companies to access contact information on registered investment advisors. Banking on the knowledge that close corporate interactions with investment advisors make it more likely that a given investment advisor will recommend a company’s stock to clients, the investment advisor feature on Sequire will seek to assist issuers in developing significant connections and ties with the investment advisor community (https://ibn.fm/0deuy).

SRAX’s corporate subscribers will be able to search and filter for specific types of advisors, designed to assist them in efficiently contacting their target audience. Moreover, in addition to assisting issuers in communicating with the advisors, the platform will also enable companies to track their subsequent participation in their listed equity.

“Registered Investment Advisors have been the largest investors in our company SRAX and have been a significant part of the growth of our shareholder base. We are now providing the tools that will enable issuers to identify, communicate with and track the progress of specific advisors,” stated Christopher Miglino.

For more information, visit the company’s websites at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $SRAX Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors

$SVFD Products Are a Major Save for Fruit at Retail Level

Save Foods (NASDAQ: SVFD) is an agri-food tech company focused on food safety and creating innovative solutions for food waste and loss. ReFED, a national nonprofit dedicated to ending food loss and waste across the U.S. food system by advancing data-driven solutions, estimates that 24% of all food in the U.S. — 54 million tons — goes to landfill, incineration, down the drain or is left in the fields to rot. “Save Foods offers the first natural product with the potential to actually replace the different chemicals with a maximum residue level used today while also addressing the challenges of both food waste and food safety,” notes a recent article. “The company’s natural treatments protect fresh fruit and vegetables from microbial spoilage and foodborne pathogens that are responsible for decay and can cause foodborne illnesses, while leaving no harmful residues on the produce or in the environment. ‘Fresh produces treated with our products can already be found in different supermarket chains across the U.S. and Europe where it was reported that Save Foods products are reducing by 50% on average the rotten fruit at the retail level,’ the company reports.”

To view the full article, visit https://ibn.fm/jTIa6

About Save Foods Inc.

Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing house processing, including citr`fruits, avocado, mango, pears, apples, and bell pepper. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co.

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at http://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $SVFD Products Are a Major Save for Fruit at Retail Level

$NEXCF to Release Q2 2021 Earnings, Schedules Earnings Call

Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a diversified leading provider of augmented reality (“AR”) solutions and services, has announced plans to release its second-quarter 2021 financial results on Aug. 11, 2021, after markets close. The company will also host a conference call to discuss its financial numbers and results on Aug. 12 , 2021, at 1 p.m. ET. Nextech CEO Evan Gappelberg and CFO Andrew Chan will host the call and provide an overview of company financial and operating results; the call will also include a question-and-answer period. Interested individuals can call in toll-free by dialing (877) 201-0168 — (647) 788-4901 for international callers — and using the conference ID 2086367. The call is also available in webcast format. A recording of the presentation will be available on the company’s website following the conclusion of the call.

To view the webcast event, visit https://ibn.fm/sU5mD

To view the full press release, visit https://ibn.fm/2nxyG

About Nextech AR Solutions Corp.

Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $NEXCF to Release Q2 2021 Earnings, Schedules Earnings Call

$LEXX Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the human response to DehydraTECH 2.0-enabled CBD. The company anticipates beginning a third human clinical study, HYPER-H21-3, following analysis of results from the first and second studies. In addition, Lexaria announced the expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is the 21st patent the company has been granted. Lexaria also noted that more than 7,000 stores across the country sell products that use its exclusive DehydraTECH technology. Some of those products include Cannadips, the original tobacco-free and nicotine-free CBD pouch; a growing number of New World CBD SKUs; and next-generation CHYLOSOMA(TM) formulations of CBD, CBG and CBN topical skin offerings. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” said Lexaria CEO Chris Bunka. “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”

To view the full press releases, visit https://ibn.fm/S0D9c and https://ibn.fm/98Kbp

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit http://www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $LEXX Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products

$FLGC Shares of Flora Growth Rise Above Previous 52-Week High

Shares of Flora Growth Corp. (NASDAQ:FLGC) traded at a new 52-week high today of $6.60. This new high was reached on above average trading volume as 940,000 shares traded hands, while the average 30-day volume is approximately 655,000 shares.

Flora Growth Corp is a vertically integrated cannabis company. It is focused on becoming the largest producer of low-cost naturally grown medicinal-grade cannabis oils, CBD-infused foods and beverages, and pharmaceutical-grade medical and cosmetic-grade derivatives from the cannabis plant. It prioritizes organic ingredients and value-chain sustainability across its portfolio to create products that help consumers restore and thrive.

Based on a current price of $5.76, Flora Growth Corp. is currently 12.0% above its average consensus analyst price target of $5.07.

In the past 52 weeks, shares of Flora Growth Corp. have traded between a low of $2.85 and a high of $6.60 and is now at $5.76, which is 102% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Wednesday, July 28th, 2021 Uncategorized Comments Off on $FLGC Shares of Flora Growth Rise Above Previous 52-Week High

$FNGR Announces Application to List Common Stock on Nasdaq Capital Market

FingerMotion (OTCQX: FNGR), a mobile data and services company, has submitted its application to have shares of its common stock listed on Nasdaq Capital Market. The company will now look to receive NASDAQ approval of the move as well as work to satisfy applicable listing, governance and regulatory requirements. During the NASDAQ review process, the company’s common stock will continue to trade on the OTCQX using the current symbol FNGR. “Over the past year, we have been working diligently to comply with certain uplisting requirements,” said FingerMotion CEO Martin Shen in the press release. “Applying for a NASDAQ listing is a key milestone in our company’s evolution. We believe listing our common stock on the Nasdaq Capital Market will improve liquidity, increase our corporate visibility and enhance shareholder value. We are excited to have submitted this application, which if approved, would see us join the ranks of global technology companies listed in the U.S. We look forward to updating shareholders on our progress in due course.”

To view the full press release, visit https://ibn.fm/9sjm1

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $FNGR Announces Application to List Common Stock on Nasdaq Capital Market

$EXN Announces Progress of Silver City Drilling Program

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) today provided an update on the ongoing drilling program at the Silver City Project located in Saxony, Germany. Among the highlights, the company reported smooth commencement of drilling at the first of four priority targets of the 12,000-metre diamond drilling program planned for 2021. In addition, a second drill rig was added to the program, with drilling now underway at the Peter Vein (Neue Hoffnung Gottes) and Bräunsdorf (Christbescherung) targets. “We have had another smooth startup of drilling at Silver City this year,” said Ben Pullinger, SVP Geology & Corporate Development. “We continue to appreciate the support of the local community and benefit from the excellent work of the TU Bergakademie Freiberg and the Helmholtz Institute of Freiberg. This year’s program builds on discoveries made last year in the first modern-day drilling for precious metals on the Bräunsdorf license. Our current drilling focusses on the historically productive gneiss-schist contact running through the Bräunsdorf and Peter Vein mines. In the coming weeks we will move up to the mafic-schist contact intersected last year at Reichenbach and Grauer Wolf, both of which yielded some of the most interesting results from drilling to date.”

To view the full press release, visit https://ibn.fm/PW1f8

About Excellon Resources Inc.

Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at http://ibn.fm/EXN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $EXN Announces Progress of Silver City Drilling Program

$CLXPF Files Patent, Adds New Dimension to Development Strategy

  • Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
  • Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
  • Cybin is confident this added focus will better enable the evaluation of patient outcomes

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy.

“The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.”

Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform.

Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model.

These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.

Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $CLXPF Files Patent, Adds New Dimension to Development Strategy

$CNSP Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of the study to treat GBM, an aggressive type of brain cancer with most treatments only slowing progression and reducing symptoms. “Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. . . . With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer. ‘Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ he explained.”

To view the full article, visit: https://ibn.fm/lsaX2

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $CNSP Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

$AMPG Positioned to Tap into Identified Opportunities

AmpliTech Group (NASDAQ: AMPG), a radio frequency (“RF”) component designer and manufacturer, recently released its Q1 report, which reflected record bookings, a record backlog and the fact that it achieved design wins reflecting its low noise amplifier (“LNA”) products’ performance, durability and heat dissipation. “While the LNA products provide significant value and return on investment for satellite network applications in space, AmpliTech sees other exciting applications,” reads a recent article. “Recently, AmpliTech received a developmental order for a special cryogenic-cooled probe head used to facilitate studies on materials, molecules and drugs to treat diseases.” According to CEO and CTO Fawad Maqbool, the company expects to benefit from the mass reopening of its market segments with the steady decline in COVID-19. “To support the substantial opportunities we have identified, we completed a recapitalization of our company over the first four months of 2021, providing over $30M in current funding to support our growth and demonstrate financial strength to our customers and partners. Additionally, we also uplisted our common stock to Nasdaq to position our company for greater visibility, liquidity and access to a much broader pool of potential investors.”

To view the full article, visit https://ibn.fm/SuYWk

About AmpliTech Group Inc.

AmpliTech Group designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G & IoT), space, defense and quantum computing markets, as well as provides systems and component design consulting services. AmpliTech has a 13+ year track record of developing high-performance, custom solutions to meet the unique needs of some of the largest companies in the global industries it serves. The company is proud of the unique skills, experience and dedication of its focused team, enabling AmpliTech to deliver superior solutions, faster time to market, competitive pricing, and excellent customer satisfaction and repeat business. For more information about the company, visit www.AmpliTechinc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at http://ibn.fm/AMPG

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, July 28th, 2021 Uncategorized Comments Off on $AMPG Positioned to Tap into Identified Opportunities

$XPHYF Danish Researchers Discover That Medical Marijuana May Combat Essential Tremor

There is huge debate on what medicinal properties, if any, marijuana possesses, and researchers are working to uncover the effects of this substance. For example, a team of researchers from the University of Copenhagen in Denmark has discovered that medical marijuana has the ability to reduce involuntary shaking or essential tremor. Their research used a mouse model.

The team’s work focused on a synthetic cannabinoid WIN55.212-2. The scientists found that when the mice were injected with this cannabinoid, astrocytes or support cells found within the brain and spinal cord of the mice were activated. When those support cells are activated, they trigger the release of adenosine, which has the effect of tamping down nerve activity and, consequently, the undesirable shaking reduces.

This study took a different approach since previous studies had focused on the neurons within the brain or spinal cord. In this study, the Copenhagen team opted to devote its attention to the astrocytes. In this way, the team has introduced a whole new perspective for other researchers who would like to investigate how medical marijuana affects its users.

Under normal circumstances, both voluntary and involuntary movements occur when the motor neurons within the spinal cord are activated. This is because the muscles are linked to the spinal cord via the motor neurons. Each time a motor neuron fires, an impulse is sent to the muscle in question, and the muscle contracts, thereby resulting in movement.

From the above, it follows that involuntary movements happen when motor neurons send impulses that conflict, thereby causing conditions such as essential tremor. This mechanism of action is what prompted the research team to study the spinal cord in relation to essential tremor.

Eva Carlsen, a postdoc student at the university who conducted all the tests during the research, explains that their work opens the door to the possibility of making medical marijuana products that target conditions that cause shaking. These include injuries to the spinal cord as well as sclerosis. Such treatments would target astrocytes or the spinal cord.

In this way, the patient would receive an effective treatment while being shielded from the side effects of the medical marijuana since the treatment isn’t being directed at the brain. For example, the cognition and memory of the patient would not be affected by the treatment administered to manage involuntary shaking.

For now, these promising research findings are only valid in mouse models, although the team hopes to embark on human tests in order to establish whether the findings observed in mice can also be replicated in humans who receive an injection of this synthetic cannabinoid.

Other researchers, such as the team at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), are looking for other ways through which neurological conditions can be addressed using cannabinoids, including cannabidiol.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $XPHYF Danish Researchers Discover That Medical Marijuana May Combat Essential Tremor

$WTER Finalizes Distribution Agreement with Largest Food Retailer in the Mid-Atlantic

  • WTER’s distribution agreement calls for Giant Food to carry select WTER Alkaline88(R) and A88 Infused(R) offerings
  • The distributor will offer WTER beverages in all 164 locations.
  • Giant Food serves market of 60 million people with over $5 billion in sales.

In an move illustrative of  its continued commitment to expansion and growth, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) announced that it has partnered with Giant Food, the largest food retailer in the Mid-Atlantic region. The distribution agreement calls for Giant Food to carry select WTER Alkaline88 and A88 Infused offerings in all locations.

“This is our biggest win to date in the Mid-Atlantic region,” said WTER president and CEO Ricky Wright. “Giant Food is the largest retailer in that market of 60 million people with over $5 billion in sales. While many retailers will test one or two product offerings, we are pleased to announce that Giant Food is carrying six products from our Alkaline88 and A88 Infused lines in their 164 locations.

“The products include our one-gallon and 1.5-liter bottles, and naturally flavored Watermelon, Raspberry, Blood Orange, and Lemon single serves,” he continued. “This year, we expect these and our other single serves to significantly increase their overall contribution to our top line. We couldn’t have hoped for a better start to our fiscal 2022 expansion into the Mid-Atlantic and Northeast regions than being on the shelves in Giant Food. This is just the beginning of a larger push into the remaining untapped markets in the U.S.”

Giant Food, a subsidiary of Ahold Delhaize, serves 164 stores in Maryland, Virginia, Delaware and Washington, DC. The company has been in operation for more than 80 years and has become an integral part of its customers’ lives and the communities it serves. The company’s commitment to providing its customers with the best is a perfect match with WTER’s dedication to offering the finest alkaline water products on the market.

WTER’s Alkaline88 is known for its superior hydration with a perfect 8.8pH balance. The brand was developed to deliver what the company calls a Deliciously Smooth(TM) taste that encourages consumers to drink more and fully hydrate. The water’s ingredient deck is simple, easy to understand and free of buffers; it contains only two ingredients: purified water and Pink Himalayan Rock Salt.

With the Giant Food announcement, the Alkaline88(R) flagship brand of premium alkaline water is now available in 75,000 stores across all trades in the United States.

For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $WTER Finalizes Distribution Agreement with Largest Food Retailer in the Mid-Atlantic

$SBEV SALT Tequila to be Launched by Leading Distributor in Florida’s Treasure Coast

Splash Beverage Group (NYSE American: SBEV), a portfolio company of leading beverage brands, today announced that Southern Eagle Distributing, the leading beverage distributor in Florida’s Treasure Coast, will market and distribute SALT Tequila to more than 2,000 retailers in its service territory this summer through numerous planned launch activities and events. “When we acquired Copa di Vino, the leading producer of premium wine by the glass in the U.S., not only did we get an iconic brand, we got access to a network of retail locations, ecommerce outlets and 82 Anheuser Busch distributors, which are now adding other Splash products to their portfolios. Our investment thesis on Copa di Vino has proven highly effective and is a model for future transactions that we anticipate will drive our growth,” said Robert Nistico, CEO of Splash. “SALT, a highly appealing brand serving one of the fastest-growing segments in spirits, will enhance Southern Eagle’s portfolio of over 700 alcoholic and non-alcoholic SKUs and we’re pleased to expand our business relationship with them.”

To view the full press release, visit https://ibn.fm/21IDa

About Splash Beverage Group Inc.

Splash Beverage Group specializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the non-alcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique as it only develops/accelerates brands it perceives to have highly visible preexisting brand awareness or pure category innovation. For more information about the company, visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at http://ibn.fm/SBEV

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $SBEV SALT Tequila to be Launched by Leading Distributor in Florida’s Treasure Coast

$SVFD Receives Seventh Global Patent for Proprietary Composition Method

July 27, 2021

Save Foods Inc. (NASDAQ: SVFD) Receives Seventh Global Patent for Proprietary Composition Method

  • Israeli Patent Office grants patent for new-generation, natural, disinfecting composition and method to protect edible matter from decay
  • Patent is further validation of SVFD’s technology, an important step in building company’s IP portfolio
  • Food waste is a social, humanitarian, economic and environment concern

Save Foods (NASDAQ: SVFD), an agri-food tech company focused on creating solutions to food waste and loss as well as food safety, has been granted its seventh global patent, protecting the company’s innovative ecofriendly product-treatment offerings (https://ibn.fm/XGHjr). The patent was granted by the Israeli Patent Office for SVFD’s new-generation natural disinfecting composition and method to protect edible matter from decay, ultimately extending extend shelf life and reduce waste.

“Israel is a world-leader in agricultural technologies and a major exporter of fresh produce,” said Dr. Neta Matis, vice president of R&D for Save Foods Ltd.’s Israel subsidiary. “Israel is a key jurisdiction for us to protect our proprietary technologies, and this patent is further validation of our technology and an important step in building an IP portfolio that ensures food safety reduce waste globally.”

The patent is Save Foods’ fourth issued patent in Israel and its seventh global patent.

These patents are representative of the success of Save Foods’ dedication to addressing two major global issues: food waste and loss, and food safety. At face value, the implications of food waste are immense, with one recent report noting that “the amount of food waste in America alone is simply mind numbing, weighing in at 133 billion pounds and $161 billion worth of food in 2010. That means 31% of all food produced annually is wasted. As a subcategory, 644 million tons of fruit and vegetables, or 42% of total supply, is wasted annually” (https://ibn.fm/MOtc3).

In fact, however, “food waste is a social, humanitarian, economic and environment concern. Understand that waste isn’t just what gets thrown away in a kitchen, grocery store or hotel. It also includes product that never leaves the farm or spoils during distribution. Collect those billions of pounds of waste, and there are enough calories to feed every undernourished person on the planet,” the report noted. “Now think about all the energy that was used, not to mention the trillions of gallons of water, to grow, harvest, package and transport the 133 billion pounds of fruit, vegetables, meat and more that ultimately ended up in the Dumpster.

“If the United States, along with the rest of the world, genuinely wants to meet carbon reduction targets by 2030, all involved need to take a close look at food waste, considering it accounts for about 8% of global emissions. According to Project Drawdown, when accounting for deforestation for farmland and annual adoption of plant-rich diets, reducing food waste by 50% to 75% by 2050 would reduce carbon dioxide emissions by up to 95.1 gigatons.”

Save Foods offers the first natural product with potential to actually replace the different highly residual (hazardous) chemicals used today while also addressing the challenges of both food waste and food safety. The company’s core applications are ecofriendly, post-harvest treatments for fruits and vegetables. SVFD’s proprietary technologies reduce the need for conventional post-harvest fungicide by at least 50% — even entirely in some cases — can reduce food loss due to spoilage by up to 50%.

The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike.

For more information, visit the company’s website at www.SaveFoods.co.

NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $SVFD Receives Seventh Global Patent for Proprietary Composition Method

$RWBYF Announces Q1 2021 Financial Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, today announced its 2021 first quarter financial results and subsequent events. “This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad Rogers, RWB’s chairman & CEO. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter. Once complete, and the expansion of our Florida operations come on stream, we can finally report in our quarterly results the strength of what we have built and accomplished thus far.”

To view the full press release, visit https://ibn.fm/3NZxo

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $RWBYF Announces Q1 2021 Financial Results

$LEXX Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine

  • The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology
  • Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization
  • The company has 20 patents granted and over 50 pending patents in over 40 countries around the world
  • The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated that administration of colchicine using the company’s proprietary DehydraTECH(TM), formulation and processing, resulted in increased delivery, according to a company press release (https://cnw.fm/p34g7).

Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines.

The study was performed using Sprague-Dawley rats, with 20 dosed through oral gavage using DehydraTECH or control colchicine formulations. Performed by an independent, premier animal testing laboratory in the United States, the study evaluated both peak concentration and total drug delivery into the rodent’s bloodstream. As colchicine has a narrow therapeutic index, which means there is a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH it can improve its bioavailability beyond current levels of approximately 45 percent, which would potentially allow lower dosing requirements.

Lexaria’s DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro, and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. This research has initiated new patent applications and opened the possibilities for improved drug delivery.

The company has licensed its proprietary technology to multiple companies for use in different industries, including tobacco and nicotine products, cannabinoid beverages and edibles and more. Lexaria’s intellectual property portfolio consists of 20 patents granted and more than 50 patents pending in over 40 countries worldwide.

Lexaria is currently collaborating with the National Research Council (“NRC”), the Canadian government’s leading research and technology organization. The Company has already filed for patent protection for specific nicotine delivery, NSAIDs, vitamins, estrogen, testosterone, terpenes, cannabinoids, PDE5 inhibitors (like Viagra), tobacco, and more.

DehydraTECH is designed for formulating and delivering fat-soluble drugs and active ingredients, increasing their effectiveness and improving the way active pharmaceutical ingredients enter the bloodstream. The benefits of a DehydraTECH-enabled drug or consumer product are:

  • Delivery is sped up, making the effects felt by the consumer in a matter of minutes
  • The bioavailability is increased, making the delivery to the bloodstream much more effective and possibly requiring lower doses
  • Animal testing has evidenced that there is a significant increase in the amount of the formulation crossing the blood barrier
  • For consumer products, eliminates or reduces the need for sweeteners that are often used to mask the unwanted taste of the substance

This technology has the potential to revolutionize the global market for advanced drug delivery systems by changing the way treatments are administered and increasing overall bioabsorption and bioavailability. The drug delivery market is expected to reach a revenue of $310 billion by 2025 from $231 billion in 2020, marking a CAGR of 6.1% (https://cnw.fm/kNJWR). Right now, one of three areas of focus for Lexaria is on the antiviral drug market, which is anticipated to reach $52.1 billion in 2021 and grow to $66.7 billion by 2025.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $LEXX Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine

$FLGC to Partner with Avaria to Bring Award-Winning KaLaya Brand to LATAM Distribution Network

Flora Growth Corp. (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced its entry into a non-binding letter of intent (“LOI”) to form a joint venture (“JV”) with Avaria Inc. Canadian-based Avaria is the manufacturer and owner of KaLaya — an award-winning pain cream distributed across Canada. Through the JV, Flora Growth will manage registration, sales and distribution of KaLaya products in Colombia, Mexico, and other LATAM countries, while Avaria will supply finished product. Flora Growth and Avaria will equally divide the profits from the sale of KaLaya products under the JV, increasing the value of Flora’s existing distribution channels. “We are very excited to partner with Avaria to bring their established, award-winning KaLaya brand to our LATAM distribution network. We believe the product will receive a similarly strong reception as it has in Canada,” said Flora Growth CEO and President Luis Merchan. “Moving forward, Flora Lab will work with the Avaria team to produce CBD-infused versions of KaLaya products for distribution across LATAM as well as export into the United States. Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally.”

To view the full press release, visit https://ibn.fm/v53Oq

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $FLGC to Partner with Avaria to Bring Award-Winning KaLaya Brand to LATAM Distribution Network

$EXN Canadian Government Invests $40 Million to Support Innovation Advancements in Mining Sector

Last week, Canadian Minister of Innovation, Science and Industry, the Honorable François-Philippe Champagne, announced that a $40 million investment would be made to the Centre for Excellence in Mining Innovation Inc. to help boost the mining sector, which is a crucial part of Canada’s economy. The investment is being made via the Strategic Innovation Fund, which has been designed to support and attract high-quality business investments across all the economy’s sectors.

The investment would support the establishment of the Mining Innovation Commercialization Accelerator Network in the country’s mining sector.

Canada is rich in critical minerals, which are crucial to the manufacturing of clean technologies, from batteries of electric cars to solar panels. Critical minerals are also utilized in the telecommunications, health care and aerospace sectors. As demand for these minerals increases, this investment would enable the country’s mining sector to deliver the minerals more efficiently and quickly, which would in turn speed up the global transition toward net-zero and position the country as a key player in the international market for net-zero technologies.

The network’s purpose would be to bring together stakeholders from various fields in an attempt to speed up the development and commercialization of innovative technologies that would make the mining sector more sustainable and productive.

The network, dubbed MICA, would operate across the country through the following partners: the College of the North Atlantic, Le Groupe MISA, MaRS, Saskatchewan Polytechnic, InnoTech Alberta, and the Bradshaw Research Initiative for Minerals and Mining.

The organization has been designed to increase the export and domestic sales of innovators in Canada, strengthen the country’s mineral supply chain, and improve the mining sector’s environmental performance and productivity as well as modernize the sector. MICA is expected to decrease the time it takes for new mineral deposits to reach the production stage, and to extend the operational lives of the mines in existence by advancing the development and commercialization of innovative, clean and autonomous technologies in the mining sector.

In addition to this, MICA, which will be based in Sudbury, Ontario, is also expected to support the commercialization of no less than 30 new processes, services or products as well as the creation of more than 10 new businesses and employment of roughly 900 people.

The initiative will also help mobilize investments of more than $100 million from the country’s private sector and extend its membership to nearly 400 organizations and businesses in Canada. This is in addition to supporting the government’s objective of making the country a leading producer of zero-emission technologies and products.

The investment made by the federal government of Canada is likely to create an even more supportive environment for mining companies such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2); ultimately, the country will be the beneficiary of such support.

NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at  https://ibn.fm/EXN

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $EXN Canadian Government Invests $40 Million to Support Innovation Advancements in Mining Sector

$CLXPF Psychedelics – Not Just for Mental Health Anymore

NetworkNewsWire Editorial Coverage: In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing therapies for hard-to-treat diseases. In November 2013, Gazyva, a drug used in combination with chlorambucil for patients with chronic lymphocytic leukemia, made history as the first breakthrough therapy to receive FDA marketing approval. Since then, hundreds of drugs have earned the designation, and several have reached commercialization. An area that remains underrepresented on the FDA breakthrough therapy list that could make waves in the coming years is that of the emerging market of psychedelics, where companies such as Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is striving to provide relief for patients with chronic pain by developing evidence-based innovation in areas where today’s approved drugs and therapies are lacking. Tryp is part of a select group of companies that are advancing or have already advanced psychedelic treatments into Phase 2 of the FDA clinical trial process, a small collection of impressive companies that includes COMPASS Pathways Plc (NASDAQ: CMPS)Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ)ATAI Life Sciences N.V. (NASDAQ: ATAI) and Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF).

  • The majority of companies in the psychedelic space are pursuing mental illnesses, with a particular affinity for depression.
  • Tryp Therapeutics is a first mover, developing a proprietary psilocybin product for two different areas with significant unmet medical need: chronic pain and eating disorders.
  • Tryp intends to submit investigational new drug applications (“IND”) to the FDA in the second half of this year.
  • Only seven companies have initiated Phase 2 clinical trials using psychedelic compounds and their market capitalizations range from $85 million to $2.7 billion — Tryp’s market cap is ~$30 million.

Opportunity Beyond Mental Illness

Many companies in the psychedelics space are leveraging data (historical, recent and anecdotal) that suggest psychedelics can be beneficial for mental disorders and diseases. These indications include post-traumatic stress disorder (“PTSD”), anxiety, attention deficit-hyperactivity disorder (“ADHD”) and different types of depression, to name a few mental illness targets. These indications, particularly depression, are receiving tremendous attention because they represent tens of millions of patients craving medication or therapy that is more efficacious with fewer unpleasant side effects than what is currently available.

While it is common knowledge that the use of psychedelic medicines such as peyote and psilocybin to produce healing effects dates back thousands of years, modern-day research was stymied by the Controlled Substances Act of 1970 that classified psychedelics as Schedule I drugs with no medical use. In the last few years, the stigma has been lifted, and research has accelerated with some promising results, such as Johns Hopkins Medicine showing that two doses of psilocybin, the psychoactive compound in “magic” mushrooms, in combination with psychotherapy produced a reduction in symptoms for adults with major depression.

While depression is a hot-button indication for several different psychedelic companies, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is confident that psilocybin can be effective in treating several other underserved indications, namely chronic pain and certain eating disorders. The San Diego-based company has assembled a seasoned management team and group of world-class advisors to lend their expertise in developing new drug candidates for chronic pain and eating disorders as part of Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN program. Tryp is using a standard oral form of synthetic psilocybin, its TRP-8802 product, for its initial Phase 2a clinical trials to demonstrate the efficacy of the compound across several indications.

Tryp is also developing a proprietary, psilocybin-based product, TRP-8803, with a novel formulation and unique route of administration. Tryp has already filed a provisional patent to protect the novel aspects of TRP-8803, which is expected to improve patients’ experiences with being treating with psychedelic compounds compared to standard oral doses.

To bring its drug products into Phase 2 clinical trials, Tryp is working with companies with world-class expertise in their respective fields. The company has partnered with Fluence on psychotherapy designs and is working with Clinlogix as the contract research organization for its upcoming clinical trials. Curia (formerly AMRI) is manufacturing the active pharmaceutical ingredient for synthetic psilocybin that forms the basis of the PFN program, while Alcami has been contracted to develop the analytical methods and final drug products for Tryp. Most significantly, Tryp has announced upcoming Phase 2a clinical trials with the Chronic Pain & Fatigue Research Center at the University of Michigan for fibromyalgia and with the University of Florida for eating disorders.

Pain: An Indication Begging for Innovation

Tryp appears to be differentiated from its group of peers in its target indications. The company’s decision to break new ground in different diseases may prove quite prescient, as it is  now a first mover in both chronic pain and certain eating disorders. As it happens, these are two potentially lucrative markets where traditional drugs seem to have fallen short in effectively treating the diseases. In chronic pain, the lack of effective treatments often drives patients to seek relief for their pain through addictive substances such as opioids that fail to treat the cause of the pain, a dangerous pattern given the more than 50,000 American lives claimed by opioid overdoses each year. The market is ripe for disruption.

Tryp recently announced that it will be conducting a Phase 2a clinical trial for fibromyalgia and has partnered with the Chronic Pain & Fatigue Research Center at the University of Michigan — the world’s first Phase 2 clinical trial for a chronic pain indication using a psychedelic chemistry.  Nearly 30% of fibromyalgia patients are using opioids to address their symptoms, and existing medications that have already been approved for fibromyalgia can be ineffective and induce significant side effects, resulting in only 10% of patients continuing to use the therapies after one year. Tryp expects to advance directly to Phase 2a clinical studies based on the significant amount of published data available on the safety of psilocybin and plans to file an Investigational New Drug (“IND”) application with the FDA for its fibromyalgia trial this quarter.

The University of Michigan will also be performing studies to advance the development of Tryp’s proprietary drug product, TRP-8803. The studies will expand Tryp’s intellectual property portfolio and will help bridge the use of TRP-8803 in subsequent Phase 2b studies and ultimate commercialization. Tryp is eager for its products to reach patients, potentially offering help in alleviating the suffering they experience from fibromyalgia and other chronic pain indications.

Eating Disorders: Starving for New Choices

In addition, Tryp is targeting an IND submission this quarter using TRP-8802 for an upcoming Phase 2a clinical trial for eating disorders including binge eating and hypothalamic obesity. Tryp will be collaborating with Dr. Jennifer Miller of the University of Florida as the principal investigator for the clinical trial. Miller is a world-renowned expert in these eating disorders and has affirmed that there are currently no approved drugs and only limited options to treat patients with rare over-eating disorders.

There has been little progress by pharmaceutical companies to develop effective treatments for eating disorders. Vyvance is an ADHD drug that Shire parlayed in 2015 into the first and only drug FDA approved for binge eating disorder (“BED”), one of the primary disorders Tryp is targeting in its upcoming trial. Both Tryp and Miller believe that patients may respond favorably to the neuroplasticity effects of TRP-8802 to help break the cycle of hunger impulses within the brain and establish new neural connections that normalize the patient’s relationship with food.

Markets Value Phase 2 Progress

Tryp will be initiating multiple Phase 2a clinical trials this year, an important milestone in the path toward commercializing its products. Drug-development companies are typically valued based on their progress toward commercialization rather than on revenue or earnings multiples; with each phase of clinical trials that are successfully completed, the likelihood of the drug product being approved to market by the FDA increases, the risk of failure is reduced, and the value of the company therefore increases. For example, the valuation of drug-development companies can increase by four times upon the successful completion of Phase 2 studies.

Given the nascency of the psychedelics market, there are only a handful of companies – seven to be exact – that have initiated Phase 2 studies. For those companies, market capitalizations range from about $85 million to $2.7 billion, providing a little color as to how the markets value companies with Phase 2 psychedelic assets. Tryp’s valuation is currently around $30 million.

Psychedelic Investing: A Trip for Everyone

The psychedelic drug-development market is maturing, and momentum will continue to build as new companies report on successful clinical trials. This is one of those rare occasions where groundbreaking opportunities abound for the benefit of patients and investors alike as an array of drug-development companies work to realize the medical potential of psychedelic-based therapies.

COMPASS Pathways Plc (NASDAQ: CMPS) is one of the first companies to focus exclusively on drug development using psilocybin. In October 2018, COMPASS was the first to receive breakthrough designation for a psychedelic from the FDA using a psilocybin therapy for treatment-resistant depression. In June 2021, COMPASS completed psilocybin administration to 216 patients in its Phase 2b clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, marking the world’s largest psilocybin therapy trial to date. The company says it is on track to deliver top-line results from the trial later this year.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), which recently uplisted to Nasdaq, is a clinical-stage biotech working on a diverse portfolio of psychedelic substances for addiction and mental illness. The company is evaluating several psychedelic chemistries including psilocybin, LSD, MDMA, DMT and 18-MC, a derivative of ibogaine. MindMed has initiated Phase 2 clinical trials in anxiety and ADHD.

ATAI Life Sciences N.V. (NASDAQ: ATAI) is the highest-valued psychedelic drug-development company with a robust portfolio and $2.7 billion market cap. The German biotech is a holding company for several start-ups conducting research with psychedelics for various mental illnesses. ATAI leverages its decentralized platform approach to incubate and accelerate companies, which include a strategic investment in COMPASS and 10 of its own programs targeting PTSD, treatment-resistant depression, opioid-use disorder, cognitive impairment associated with schizophrenia, general anxiety and mild traumatic brain injury.

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Toronto-based Cybin’s lead drug program is CYB001, a sublingual film psilocybin product for major depressive disorder. A Phase 2a clinical trial will evaluate five different dosing regimens across 40 patients before the study advances into a Phase 2b study that is expected to enroll 120 patients.

It is an exciting time for the psychedelic drug-development industry, with new trials coming online and results from the biggest clinical trial yet expected in the coming months, which has potential to catalyze the entire sector.

For more information about Tryp Therapeutics, please visit Tryp Therapeutics Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, July 27th, 2021 Uncategorized Comments Off on $CLXPF Psychedelics – Not Just for Mental Health Anymore

$XPHYF Analysis Suggests No Link Between Psychedelics and the Onset of Mental Health Conditions

Researchers theorize that psychedelic substances differ from other recreational drugs because they do not lead to compulsive use or addiction and neither do they harm an individual’s brain. An analysis conducted by researchers from the Department of Neuroscience at the Norwegian University of Science and Technology proves this, having found that the use of peyote, psilocybin mushrooms or LSD does not increase an individual’s risk of developing mental health conditions.

They also found no association between various mental health conditions and the use of psychedelic substances, but they did discover significant links between fewer metal health issues and the use of psychedelic substances.

Pål-Ørjan Johansen, who is a clinical psychologist, and Teri Krebs, who were both part of the study, utilized data obtained from a national health survey conducted in the United States between 2001 and 2004, which had more than 130,000 participants, including more than 20,000 individuals who had used psychedelics at least once.

The study was reported in the “PLOS ONE” journal.

Johansen explained that while every substance had some potential for negative effects, the use of psychedelics was generally considered to pose a very low risk to society and to the individual, adding that psychedelics were known to induce temporary feelings of confusion and anxiety but accidents that caused serious injuries were very rare.

During the survey, each participant was asked about mental health symptoms and treatments for a variety of mental health conditions, with a focus on psychosis, mood disorders, anxiety disorders and psychological distress. This information allowed the researchers to assess if there were any links between specific or general mental health problems and the use of psychedelics.

Johansen stated that after they’d adjusted for other risk factors, the researchers found that past-yearuse of LSD and lifetime use of mescaline or psilocybin was linked to lower rates of severe psychological distress. Lifetime use of LSD was also considerably linked to lower rates of psychiatric medicine prescription and outpatient mental health treatment.

In the report, the researchers observed that despite these findings, they couldn’t rule out the possibility that using psychedelic drugs may have a negative effect on mental health for some groups or individuals. However, they noted that clinical trials had also not found any evidence of lasting harmful effects of psychedelic drugs, with Johansen adding that other studies had discovered no evidence of social or health problems among individuals who had consumed psychedelics a number of times in religious ceremonies that were legally protected.

This long history of psychedelic use by various communities means that companies such as XPhyto Therapeutic Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) may not have a lot of work to do to prove the safety profile of medicines made from psychedelics, including psilocybin and MDMA.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $XPHYF Analysis Suggests No Link Between Psychedelics and the Onset of Mental Health Conditions

$WTER Stands Distinct in Water Provision

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), the country’s largest independent alkaline water company, recently announced plans to join the Russell Microcap(R) Index. “Russell Indexes are part of FTSE Russell, a leading index provider known for providing critical, innovative benchmarking, analytics and data solutions for investors around the world,” reads a recent article. “Along with membership in the Russell Microcap Index comes automatic inclusion in other appropriate growth and value style indexes. Membership in those indexes is determined by FTSE Russell based on objective, market-capitalization rankings, and style attributes. The Alkaline Water Company’s inclusion in the indexes is clear evidence of its success in building a strong, successful beverage portfolio that includes Alkaline88(R), A88 Infused(R) and A88CBD(TM). The company is dedicated to purity, quality, value and taste, and is focused on making a difference in the water people drink.”

To view the full article, visit: https://cnw.fm/eNZ7z

About The Alkaline Water Company Inc.

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with ecofriendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts WTER’s trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique, all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products Inc. includes the company’s lab-tested, hemp-extract salves, balms, lotions, essential oils, bath salts, powder packs, oil tinctures, capsules and gummies. To purchase Alkaline88 and A88 Flavor Infused products online, visit www.Alkaline88.com. To learn more about the company, visit www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $WTER Stands Distinct in Water Provision

$SRAX to Host 2021 LD Micro Main Event In-Person and Virtually

SRAX (NASDAQ: SRAX)a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has announced that it will host the 2021 LD Micro Main Event both in-person in Los Angeles and virtually via its Sequire Virtual Events platform. The event, slated to take place on October 12-14, 2021, marks the first in-person conference for LD Micro in almost two years and brings physical and virtual elements together to form a truly unique experience. “About time,” stated Chris Lahiji, founder of LD Micro. “It has been nearly two years since our last physical conference. I wanted our 14th installation to host all the executives and investors that supported us. I’ll be looking forward to greeting everyone with fist bumps, chest bumps and hugs.” The link to register for virtual and physical components of the event, which is expected to feature around 150 companies, presenting for 25 minutes each, will be released soon.

To view the full press release, visit https://ibn.fm/pEgOU

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and www.MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $SRAX to Host 2021 LD Micro Main Event In-Person and Virtually

$NEXCF Unveils Plans to Launch AR NFT Hologram Creator Platform

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, today announced plans to launch its NFT hologram creator platform. The new offering will leverage the company’s human hologram creator platform HoloX. Upon expected launch in the third quarter, customers will have the ability to seamlessly experience digital collectibles in augmented reality. “This is an exciting new market opportunity for our company and, when the NFT-enabled platform is completed, it will squarely put us into the world of blockchain by merging our AR tech with NFT technology,” said Evan Gappelberg, CEO of Nextech. “Our AR creation technology leverages AI allowing us to scale up the production of high-quality and personalized content as a hologram NFT, be it your favorite athletes, artist or artwork. We are continuing to build leading-edge AR solutions for fast growing industries by coming up with innovative ways of leveraging our tech stack. Our goal has always been to create long-term shareholder value and with this new AR NFT innovation I believe we are succeeding at doing just that.”

To view the full press release, visit https://ibn.fm/kuryC

About Nextech AR Solutions Corp.

Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences, altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance), as well as learning and training experiences. Nextech focuses on developing AR solutions; however, most of the company’s revenues are currently derived from three ecommerce platforms, VacuumCleanerMarket.com (“VCM”), InfinitePetLife.com (“IPL”) and TruLyfeSupplements.com (“TruLyfe”), as well as VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, visit www.NextechAR.com.

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $NEXCF Unveils Plans to Launch AR NFT Hologram Creator Platform

$LEXX Secures $3.8M Through Warrant Exercises

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of US$3,817,643 from the exercise of share purchase warrants. According to the update, the company issued the warrants pursuant to its January 2021 public underwritten offering. The shares and warrants issued thereunder were registered pursuant to a Form S-1 Registration Statement (No. 333-250326), as amended, and a Form S-1MEF Registration Statement (No. 333-252031). The warrants were exercised into 580,189 shares of voting common stock of the company, each at an exercise price of US$6.58. The company will utilize all proceeds received from the warrant exercises for the continued advancement of its investigational research program and for general corporate purposes. With this additional capital, Lexaria Bioscience Corp. believes its business plan objectives and all operations are now funded well into the year 2022.

To view the full press release, visit https://ibn.fm/EPIyH

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $LEXX Secures $3.8M Through Warrant Exercises

$IDEX to Release its 2021 Q2 Financial Results on Monday, August 16, 2021

  • Ideanomics plans to release its 2021 second-quarter financial results on Monday, August 16, 2021
  • The press release is scheduled at 4 pm ET and will be followed by a conference call at 4:30 pm ET
  • The call will have the company’s senior management sharing their thoughts on the company’s performance
  • It will also have a question-and-answer session for the audience

Ideanomics (NASDAQ: IDEX) will release its 2021 second-quarter financial results on Monday, August 16, 2021. The press release will be issued at 4 pm ET and will be accompanied by a conference call at 4:30 pm ET (https://ibn.fm/uDgF9).

The event will feature Ideanomics’ senior management, where they will share their thoughts on its performance so far in the 2021 fiscal year. The session will also provide engagement with the audience, where attendees will get the chance to ask the management questions and have the latter respond to them (https://ibn.fm/x7xbE).

Ideanomics is a company that is playing a pivotal role in the adoption of commercial electric vehicles. Its business also involves offering support for next-generation financial services and fintech products. The company is more known known, specifically for its electric vehicle division, Ideanomics Mobility. Ideanomics also has a fintech side to their business under the Ideanomics Capital division.

Should you be interested in attending the virtual conference, there are two options to choose from, namely:

  1. Webcast Link: https://ibn.fm/30z5X
  2. Dial-in Number: 877-407-3107 or 201-493-6796 (Toll-Free for the United States) and Canada

To view the replay of the virtual conference and read the earnings material, check out the company’s investor relations website https://investors.ideanomics.com.

For more information, visit the company’s website at www.Ideanomics.com.

NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $IDEX to Release its 2021 Q2 Financial Results on Monday, August 16, 2021

$FLGC Positioned to Benefit from Revised Colombian Regulations, Is Covered by Argus Research Report

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, has announced that new Colombian regulations allow the company to increase revenue both long and short term. The regulations also enhance the company’s global supply chain of premium brands and products, and expand economics both domestically and abroad. The changes were made when the president of Colombia accepted and signed into effect revisions to existing Colombian cannabis laws. Revisions now allow for the sale and export of raw cannabis materials, including dried flower, to international markets. In addition, Colombian cultivators are now positioned to be leading suppliers to the global cannabis market. The revised regulations also permit the manufacturing, sale and export of ingestible cannabinoid products in Colombia, providing near-term revenue potential for Flora’s Kasa Wholefoods division. “This legislative update immediately accelerates Flora’s ability to generate revenue through the sale of our cannabis flower to international markets, as noted by our first international supply agreement. Having the ability to export our high-margin, high-quality cannabis flower – in addition to selling cannabinoid ingestible products – will meaningfully impact our growth and revenue generation,” Flora Growth Chief Revenue Officer Jason Warnock stated in the news release. “We are very excited to leverage our existing product portfolio and distribution channels to quickly deliver these new products to Colombians and our international partners.”

In addition, Argus Research, an independent investment research firm, released an Equity Research Report coverage on Flora Growth. The report noted that FLGC leverages cost-effective cannabis cultivation in Colombia and supplies cannabis as well as its derivatives for an expanding range of products, including cosmetics, pharmaceuticals, food and beverages, and hemp-based textiles. The report noted that FLGC’s Colombian cultivation operation benefits from favorable weather and produces harvest year-round, with costs lower than other Colombian producers. “In our view, Flora Growth is well positioned to participate in a global cannabis market that BDS Analytics projects will reach $56 billion by 2026, up from $21 billion in 2020,” the report states.

To view the full research report, visit https://ibn.fm/f9sWl

To view the full press releases, visit https://ibn.fm/aNYdV and https://ibn.fm/ZD7DZ

About Flora Growth Corp.

Flora Growth is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at http://ibn.fm/FLGC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, July 26th, 2021 Uncategorized Comments Off on $FLGC Positioned to Benefit from Revised Colombian Regulations, Is Covered by Argus Research Report

$UUUU Worldwide Uranium Production Set to Register 3.1% Recovery in 2021

Figures show that the global production of uranium will recover by more than 3% this year, owing to the resumption of operations at Canada’s Cigar Lake mine as well as other mines that were suspended last year. In addition, while the mineral’s production in Australia will continue to decrease because of the halt in operations at the Ranger mine, Russia and Kazakhstan will record significant increases in their output.

In the recent past, international production has been limited, primarily because of a slow uranium market, which was affected by the coronavirus pandemic. Last year, global uranium production decreased by more than 9%, with the most notable declines being observed in Kazakhstan and Canada. These two countries produce a combined 60% of the mineral globally.

In March last year, operations at the Cigar Lake mine, which makes up roughly 13% of global production, were suspended until September in an attempt to prevent the virus from spreading.

After resuming operations, mining was again suspended in December 2020 due to the increased risk of coronavirus infections; in April of this year, the mine finally reopened again. This move will boost the supply of uranium from Canada. Kazakhstan also decreased activities at its uranium mines for more than four months at the height of the pandemic last year. These were not the only countries affected by the pandemic as countries such as South Africa, Namibia and Australia also imposed restrictions.

Projections show that between 2021 and 2025, the global production of uranium will grow at a compound annual growth rate of about 6%, reaching more than 65kt by the year 2025. Kazakhstan is expected to remain the biggest supplier of the mineral globally as it holds some of the biggest uranium deposits in the world. Namibia, which has open-pit uranium mines, may also be among the main suppliers of uranium to the international markets.

Many believe the early implementation of safety measures reduced the effect of the pandemic on the international nuclear industry and allowed for operations to continue with minimal disruptions.

As more governments incorporate nuclear energy into their plans to attain climate goals, optimism surrounding the international nuclear industry continues to rise.

A good example would be the United States, which is currently the biggest producer of nuclear energy globally, with Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) being the largest U.S. producer of this energy-dense mineral. The country is currently debating on whether it shouls extend the operating life of its plants to a hundred years.

The European Union as well as countries such as South Korea and Japan also updated their climate change policies last year, with many anticipating an increase in demand for nuclear energy in the near future.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

are available in the company’s newsroom at http://ibn.fm/UUUU

Monday, July 26th, 2021 Uncategorized Comments Off on $UUUU Worldwide Uranium Production Set to Register 3.1% Recovery in 2021

$XPHYF Researchers Compare COVID-19 to Other Respiratory Ailments

A group of researchers from the United States and Israel conducted a study that compared the disease progression and presentation between in-hospital patients suffering from COVID-19 with other respiratory ailments such as influenza. They discovered that coronavirus patients displayed a unique cardiorespiratory, immune and metabolic profile, noting that the disease’s severity was higher in comparison with other respiratory illnesses.

The virus that causes the coronavirus, SARS-CoV-2, is a deadly and highly infectious virus. It has infected more than 190 million individuals and claimed more than 4 million lives across the globe, despite the effective control measures that were implemented in a timely fashion to contain its spread.

Coronavirus-associated pneumonia is recognized as one of the main causes of higher mortality, among other pathological characteristics. The approaching winter season is expected to cause an increase in the number of respiratory ailments, including SARI (severe acute respiratory infection) and seasonal influenza as well as coronavirus cases.

This is why researchers deem it important to assess the differences in the clinical progression and presentation between the coronavirus and other respiratory infections in order to not only understand its prognosis but also identify features that are specific only to the coronavirus.

For their study, the researchers conducted an analysis of the electronic medical records of 8,651 patients suffering from different respiratory ailments who had been admitted to Israel’s Rambam Health Care Campus. The analysis, which evaluated comorbidities, lab findings, vital signs and patients’ demographic characteristics as well as mortality rates, was used to determine the ailment’s fatality and severity.

The researchers discovered that only about 25% of coronavirus patients were aged 75 and above, in comparison to 40% of SARI and influenza patients. In addition, they found that while 50% and 52% of influenza and coronavirus patients respectively were male, roughly 58% of SARI patients were male, noting that Arabs were more susceptible to contracting the coronavirus in comparison with SARI and influenza.

Furthermore, their findings showed that in comparison with SARI and influenza patients, comorbidities such as hypertension, cardiovascular and pulmonary problems and cancer was less frequent in coronavirus patients. Coronavirus patients also demonstrated higher diastolic blood pressure and lower systolic blood pressure and heart rate, compared to SARI patients.

The researchers reported no considerable differences in body temperature, breathing rate and oxygen saturation were observed. With regard to lab findings, coronavirus patients demonstrated higher lymphocyte count and lower neutrophil and white blood cell counts, compared to SARI and influenza patients.

The increased understanding that the research community has gained about the coronavirus behind COVID-19, combined with innovations from companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), offers hope that this pandemic will be contained sooner rather than later.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, July 23rd, 2021 Uncategorized Comments Off on $XPHYF Researchers Compare COVID-19 to Other Respiratory Ailments

$WTER Record Revenue Streak Continues

  • The company’s FY 2021 numbers show record revenue of $46 million, a 20% year-over-year increase
  • WTER issues guidance for the full FY 2022 of $62 million, which would represent year-over-year growth of 35%
  • In addition to significant financial highlights, the FY 2021 report noted key operational milestones

As The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) continues its focus on consistent growth and expansion, its financial reports are tangible proof of the success of those efforts. The company’s FY 2021 numbers show record revenue of $46 million, a 20% year-over-year increase for the country’s largest independent alkaline water company (https://cnw.fm/1Ymfg).

“Fiscal 2021 was another record year for The Alkaline Water Company continuing our streak of never having a down or a flat year,” said company president and CEO Richard A. Wright. “Our employees and business partners rose to the occasion throughout last year, and we have seen significant sales acceleration into fiscal 2022. We delivered to our customers and consumers when they needed us most.

“The trust and appreciation we earned from our strong performance throughout the pandemic allowed us to continue to see more organic and new-store growth, and an expanding presence in more key channels,” Wright continued. “Our guidance for the full fiscal year 2022 is $62 million, which would represent year-over-year growth of 35%.”

In addition to the $46 million record revenue, WTER’s financial report for the period ending March 31, 2021, included compound annual growth rate (“CAGR”) of 52% for revenue since fiscal 2015; cost of Goods sold equal to an estimated $29.6 million, which represents a 17% increase over FY 2020; gross profit of some $16.4 million, a 25% increase over the $13.1 million reported in fiscal 2020. In addition, the company reported cash or cash equivalents of more than $9 million.

In addition to financial highlights, the FY 2021 report noted key operational milestones, including the fact that the company’s flagship product, Alkaline88(R) water, is now available in more than 75,000 stores across the country. The company also launched its Direct Store Delivery (“DSD”) strategy with Mahaska, Nevada Beverage Company and Hensley Beverage, which combined serve 16,000 clients in five states.

WTER also noted significant expansion efforts, including its first move across borders through its international distribution agreement with Mexico-based Tiendas Sindicales, which sells to approximately 6 million customers a month in the Mexican Free Trade Zone. The company also expanded into the multibillion-dollar hospitality and food-service channel through key partnerships with Dot Foods Inc., the largest food redistributor in the United States, and Independent Broker Alliance (IBA Foodservice), an alliance of 30 independently owned and operated foodservice sales agencies.

“During Fiscal 2021, we tightened our supply lines, met production demands and added talented employees to our mix,” Wright states. “While the hospitality industry as a whole was disrupted last year, we made significant strides to position ourselves well for channel penetration. We partnered with the largest food redistribution company in the U.S., Dot Foods, and national broker IBA Foodservice. We expect these partnerships to bear fruit in fiscal 2022 as the hospitality industry opens up and on-premise consumption makes a significant comeback.

Wright also noted that WTER received new export certificates from the FDA and now have three co-packers that are certified to export. “We expanded into our first international market, with Tiendas Sindicales in Mexico,” he said. “We’re excited for what this means for The Alkaline Water Company, as Mexico has one of the highest per capita bottled water consumption rates in the world. Expansion into the Caribbean and Puerto Rico is already underway in fiscal 2022, and we are confident that Canada can be our next international market.”

Looking forward, the company expects to deliver revenue of $62 million, with an estimated gross profit of approximately $23.5 million, according to WTER chief financial officer David Guarino. “This represents revenue growth of approximately 35% for the full year. We expect our top line to be driven primarily by the momentum we’re carrying forward from a successful 2021, which has resulted in SKU expansion, a gain in traction for our single-serves, and significant organic growth within our existing retail clients. This momentum should also allow us to see expanded distribution to additional retailers throughout the country.”

For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Friday, July 23rd, 2021 Uncategorized Comments Off on $WTER Record Revenue Streak Continues